A large-scale study led by researchers at the University of Nottingham has revealed that urate-lowering medications, particularly allopurinol, not only alleviate the painful symptoms of gout but also significantly reduce the risk of heart attacks, strokes, and cardiovascular death. The findings, published in JAMA Internal Medicine, indicate that patients achieving serum urate levels below 360 micromol/L (6 mg/dL) experience better cardiovascular outcomes over five years compared to those who do not reach this target.

The study analyzed data from nearly 110,000 gout patients using an emulated target trial approach, linking primary care records with hospital and mortality data. Results showed that patients who successfully lowered their urate levels had a lower incidence of major cardiovascular events and higher survival rates. Notably, the protective effect was amplified in individuals with pre-existing high cardiovascular risk, and those achieving even lower urate levels (below 300 micromol/L (5 mg/dL)) experienced even greater reductions in risk.

These findings underscore the dual benefits of urate-lowering therapy, shifting the paradigm of gout management to encompass cardiovascular health. This research suggests that clinicians should prioritize achieving target urate levels not only to prevent gout flares but also to mitigate cardiovascular risks, potentially influencing treatment protocols and timelines for drug development in the context of multi-morbidity management.

Source: sciencedaily.com